Furthermore, 1,25D treatment reduces claudin1 expression, AKT activation, and cancer cell stemness by inhibiting β-catenin and reverses claudin1 and AKT activation mediated-cancer stem-like properties and gefitinib resistance (Fig. 8J). Here, CLDN7 is linked to cancer.